Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WGS vs ADPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

WGS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

WGS Overall Winner 6-Pillar Tally: WGS 4 – 2 ADPT Matrix Metrics: WGS 5 – 5 ADPT

As of Nov 16, 2026, GeneDx Holdings Corp. (WGS) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WGS carries a Unified Composite Score of 49.5/100 (HOLD) at $51.02 (40.6x Forward P/E, -13.7% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $27.87 (N/M Forward P/E, -16.2% operating margin).

  • Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WGS vs ADPT
WGS NASDAQ Head-to-Head Winner
GeneDx Holdings Corp. Class A Common Stock
Services-Health Services
$51.02
-2.58% 1D
Market Cap $1.6B
TTM Revenue $461M
Forward P/E 40.6x
Beta / 30D Vol 1.74β · 111% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 35
RSI-14: 34.8 · SMA20: $62.47 · SMA50: $73.13
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$27.87
-4.03% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.74β · 60% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 52
RSI-14: 51.8 · SMA20: $27.26 · SMA50: $26.98

6-Pillar Scorecard Institutional Category Breakdown (WGS 4 – 2 ADPT)

Columns: Metric · WGS · ADPT
1. Valuation Multiples WGS
Forward P/E 40.6x N/M
Trailing P/E 38.8x N/M
PEG Ratio N/M N/M
EV / Revenue 3.7x 16.9x
2. Growth & Scale WGS
Revenue Growth (YoY) +5.4% -10.7%
Earnings Growth (YoY) +0.0% -70.1%
TTM Revenue (USD) $461M $298M
Market Cap $1.6B $4.7B
3. Profitability & Quality WGS
Gross Margin 68.8% 46.2%
Operating Margin -13.7% -16.2%
Net Profit Margin -24.1% -23.7%
Return on Equity (ROE) -41.4% -36.4%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) -$101M -$8.8M
Cash Flow Margin -22.0% -3.0%
Net Cash / Leverage $119M Net Debt (0.88x D/E) $333M Net Debt (2.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 102.3% (21st %ile) 78.0% (36th %ile)
Put/Call OI Skew 7.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat WGS
OpEx & R&D Intensity 82.5% of Rev ($380M) 62.4% of Rev ($186M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WGS (5) vs ADPT (5)
Institutional Metric WGS ADPT Criterion Row Edge
Market Capitalization
Scale
$1.6B $4.7B Larger Scale ADPT
Trailing P/E Ratio
Valuation
38.8x N/M Lower Multiple WGS
Forward P/E Ratio
Valuation
40.6x N/M Lower Multiple WGS
Revenue Growth (YoY)
Growth
+5.4% -10.7% Higher Growth WGS
Operating Margin (TTM)
Profitability
-13.7% -16.2% Higher Margin WGS
Net Profit Margin
Profitability
-24.1% -23.7% Higher Margin ADPT
Return on Equity (ROE)
Capital Efficiency
-41.4% -36.4% Higher ROE ADPT
52-Week Range Position
Momentum
14% ($32–$171) 78% ($12–$32) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
1.74β · 111% Vol 1.74β · 60% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
49.5 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite WGS
Trailing 12M Revenue (USD)
Operating Scale
$461M $298M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.8% 46.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.7x EV/Rev N/M PEG · 16.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$101M ($119M Net Debt (0.88x D/E)) -$8.8M ($333M Net Debt (2.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADPT +35.82 pp
WGS: -19.79% · ADPT: +16.03%
3M Horizon ADPT +46.65 pp
WGS: -33.17% · ADPT: +13.48%
6M Horizon ADPT +99.77 pp
WGS: +19.51% · ADPT: +119.28%
1Y Horizon ADPT +157.96 pp
WGS: -60.86% · ADPT: +97.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period WGS Revenue ADPT Revenue WGS Op. Margin ADPT Op. Margin Margin Leader
FY2018 N/A $60M N/A -89.4% ADPT
FY2019 $200M $90M -15.5% -92.1% WGS
FY2020 $180M $100M -134.9% -155.3% WGS
FY2021 $210M $150M -210.3% -135.4% ADPT
FY2022 $230M $190M -284.5% -108.0% ADPT
FY2023 $200M $170M -89.2% -133.3% WGS
FY2024 $310M $180M -7.6% -90.8% WGS
FY2025 $430M $280M -3.1% -20.6% WGS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WGS BREAKDOWN
96d in phase · OBV DISTRIBUTION
Current IV 102.3%
IV Percentile 21st %ile
Put/Call OI Skew 7.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact WGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADPT CONSOLIDATION
69d in phase · OBV ACCUMULATION
Current IV 78.0%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WGS Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.6B market capitalization and -13.7% operating margin.
OpEx & R&D Reinvestment 82.5% of Rev ($380M)
90D Engineering Disclosures 0 Published
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published

Investor FAQ WGS vs ADPT Key Questions & Quantitative Answers

As of Nov 16, 2026, GeneDx Holdings Corp. (WGS) is the stronger overall head-to-head candidate over Adaptive Biotechnologies Corporation (ADPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WGS carries a Unified Composite Score of 49.5/100 (HOLD) at $51.02 (40.6x Forward P/E, -13.7% operating margin), whereas ADPT carries 43.8/100 (HOLD) at $27.87 (N/M Forward P/E, -16.2% operating margin). Technical & Structure Timing Caution: WGS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile ADPT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

WGS leads the Growth & Scale pillar: WGS posts +5.4% YoY revenue growth and +0.0% YoY earnings growth on $461M TTM revenue (68.8% gross margin, -13.7% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), WGS cumulative revenue shifted +115.0% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, WGS deploys 82.5% of Rev ($380M) (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.

WGS screens cheaper on headline valuation multiples. WGS trades at 40.6x Forward P/E, 38.8x Trailing P/E, N/M PEG, and 3.7x EV/Revenue (-22.0% FCF margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WGS (-41.4% ROE) versus ADPT (-36.4% ROE) capital efficiency.

In options market volatility and institutional positioning, WGS carries 102.3% implied volatility (21st %ile, Compressed (<25th %ile)), a 7.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 111% Vol realized risk). By comparison, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Adaptive Biotechnologies Corporation Common Stock (ADPT) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.